The U.S. Food and Drug Administration (FDA) has approved Nulojix (belatacept) for prevention of acute rejection in adult patients who have had a kidney transplant. Read more.
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.